SAN FRANCISCO, Feb. 28, 2022 /PRNewswire/ -- Nektar Therapeutics (Nasdaq: NKTR) today reported financial results for the fourth quarter and full year ended December 31, 2021. Cash and investments in marketable securities at December 31, 2021 were approximately $0.8 billion as compared to...
News Ticker
- [ March 25, 2023 ] Research Associate II/III, Assay Development – Triplebar – Emeryville, CA San Francisco Biotech Jobs
- [ March 25, 2023 ] Regional Marketing Manager – Rylaze – Jazz Pharmaceuticals – Palo Alto, CA San Francisco Biotech Jobs
- [ March 25, 2023 ] Cheminformatics Senior Scientist, ADME – Atomwise – San Francisco Bay Area, CA San Francisco Biotech Jobs
- [ March 25, 2023 ] Senior Scientist/Staff Scientist, Molecular Biology – Inscripta Inc – Pleasanton, CA San Francisco Biotech Jobs
- [ March 25, 2023 ] Senior Research Associate/Scientist I, Synbio – Inscripta Inc – Pleasanton, CA San Francisco Biotech Jobs
Copyright © 2022 Biotech Networks, LLC
